Beyond Dual Bronchodilation – Triple Therapy, When and Why
Open Access
- 1 January 2022
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 165-180
Abstract
Although pharmacological treatment of COPD is codified in different guidelines and strategy documents, there is abundant evidence of discrepancy between what they suggest and what health professionals prescribe, especially in low-risk groups where there is widespread overprescription of triple therapy. It is therefore necessary to clarify when the use of triple therapy is indicated in COPD patients and when it is preferable to maintain treatment with dual bronchodilation. In this article, we discuss our views based on our experience and what is reported in the literature and try to give answers to these two questions. The evidence generated by pivotal RCTs supports the use of triple therapy in patients who present for the first time and have severe airway obstruction, are symptomatic, have had frequent moderate or severe exacerbations in the previous year, and have peripheral eosinophilia. However, it is difficult to determine whether step-up is useful in all other cases because the available data are quite conflicting. It is likely that the inconsistency in the information generated by the various available studies may explain the prescribing behaviour of many physicians who do not adhere to recommendations of guidelines and strategies. However, it is necessary to establish whether and when the addition of an ICS to the LAMA/LABA combination is effective, to determine whether triple therapy can induce an additional clinical benefit over dual bronchodilation, irrespective of a preventive effect on COPD exacerbations, to establish its value, and to examine whether cost differences can support the use of triple therapy over combined LAMA/LABA therapy in real life.Keywords
This publication has 79 references indexed in Scilit:
- Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEuropean Journal of Pharmacology, 2015
- Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchiEuropean Journal of Pharmacology, 2015
- Inhaled corticosteroids: potency, dose equivalence and therapeutic indexBritish Journal of Clinical Pharmacology, 2015
- Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPDAnnals of the American Thoracic Society, 2015
- Triple combinations in chronic obstructive pulmonary disease – is three better than two?Expert Opinion on Pharmacotherapy, 2014
- Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary diseaseThe Lancet Respiratory Medicine, 2014
- β2-Agonist Therapy in Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortalityThorax, 2012
- Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their BiomarkersAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Outcomes for COPD pharmacological trials: from lung function to biomarkersEuropean Respiratory Journal, 2008